Banner Description Donec justo odio, lobortis eget congue sed, rutrum sit amet mauris. Curabitur sed lectus nulla. Curabitur sed lectus nulla.lobortis eget congue sed, rutrum sit amet mauris. Curabitur sed lectus nulla rutrum sit amet mauris
Bieche We, Parfait B, Tozlu S, Lidereau R, Vidaud Meters: Quantitation out of androgen receptor gene phrase into the sporadic nipple cancers because of the real-big date RT-PCR: proof one MYC is an enthusiastic AR-managed gene. Carcinogenesis. 2001, twenty two (9): 1521-1526. /carcin/twenty-two.9.1521.
Bratthauer GL, Lininger RA, Man YG, Tavassoli FA: Androgen and you can estrogen receptor mRNA standing in the apocrine carcinomas. Diagn Mol Pathol. 2002, eleven (2): 113-118. 9606-200206000-00008.
Gatalica Z: Immunohistochemical studies of apocrine nipple sores. Uniform more than-term regarding androgen receptor accompanied by the increased loss of estrogen and progesterone receptors during the apocrine metaplasia and you may apocrine carcinoma into the situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.
Soreide JA, Lea OA, Varhaug JE, Skarstein An effective, Kvinnsland S: Androgen receptors during the operable cancer of the breast: reference to other steroid hormones receptors, correlations so you’re able to prognostic items and you can predictive worth to possess effect of additive tamoxifen therapy. Eur J Surg Oncol. 1992, 18 (2): 112-118.
Bayer-Gather IB, Smoller B: Androgen receptors: a beneficial marker to boost susceptibility for determining cancer of the breast into the epidermis metastasis off unfamiliar pri, thirteen (2): 119-122. /modpathol.3880021.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic pastime and you will health-related implications. J Clin Oncol. 2000, 18 (5): 1135-1149.
Pang ST, Flores-Morales An effective, Skoog L, Chuan YC, Nordstedt Grams, Pousette Good: Control away from matrix metalloproteinase thirteen term from the androgen when you look at the prostate cancer. Oncol Representative. 2004, eleven (6): 1187-1192.
Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)<2436::AID-CNCR2820541121>3.0.
Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Review of your prognostic dependence on androgen receptor term when you look at the metastatic cancer of the breast. Virchows Arc. 2006, 449 (1): 24-31. /s00428-006-0213-6.
Parker RL, Hunter DG, Lesack DW, Cupples JB, Give DR, Akbari Yards, Gilks CB: Comparison out of interlaboratory adaptation about immunohistochemical commitment away from estrogen receptor status having fun with a cancer of the breast muscle microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.
Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Study of matrix metalloproteinases and their inhibitors in the cancer of the breast. Br J Malignant tumors. 2007, 96 (6): 903-911. manhunt nedir /sj.bjc.6603666.
Narita D, Raica Meters, Suciu C, Cimpean A good, Anghel A beneficial: Immunohistochemical expression of androgen receptor and you may prostate-particular antigen into the cancer of the breast. Folia Histochem Cytobiol. 2006, 49 (3): 165-172.
Egeblad Yards, Werb Z: The fresh new services into the matrix metalloproteinases inside malignant tumors advancement. Nat Rev Cancers. 2002, dos (3): 161-174. /nrc745.
Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–on chief phase off cancers?. Cancer tumors Phone. 2004, 5 (5): 409-410. /S1535-6108(04)00117-5.
Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira Elizabeth, Martinez Air-conditioning: The brand new matrix metalloproteinase-nine handles the latest insulin-for example development foundation-caused autocrine impulse during the DU-145 carcinoma tissue. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..
Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel Elizabeth, Matrisian LM, Mareel Yards: Release of an invasion promoter Age-cadherin fragment by matrilysin and stromelysin-step 1. J Phone Sci. 2001, 114 (Pt 1): 111-118.
Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] term chooses to have muscle with reduced awareness in order to apoptosis. Neoplasia. 2001, step three (6): 459-468. /sj.neo.7900190.
Stetler-Stevenson WG: Matrix metalloproteinases inside angiogenesis: a relocation target having therapeutic intervention. J Clin Invest. 1999, 103 (9): 1237-1241. /JCI6870.
Cornelius Los angeles, Nehring LC, Harding E, Bolanowski Yards, Welgus HG, Kobayashi DK, Penetrate RA, Shapiro SD: Matrix metalloproteinases create angiostatin: consequences on neovascularization. J Immunol. 1998, 161 (12): 6845-6852.
Jiang Y, Goldberg ID, Shi YE: Cutting-edge spots away from structure inhibitors of metalloproteinases in cancer. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.
